Plasma Alzheimer"s assays agree on level but much less on individual rates of change
En palabras de los autores
INTRODUCTION: Serial plasma testing is proposed for monitoring Alzheimer's disease and for trials, but its reliability for a person's rate of change is unknown. METHODS: In 393 ADNI participants with three plasma samples over a median 5.0 years, 15 measures of five biomarkers were assayed on aliquots of the same samples, separating shared change from assay-specific variation at each sampling occasion. Results were tested in 1,093 A4/LEARN participants. RESULTS: Assays agreed well on cross-sectional levels (intraclass correlation 0.75--0.95 for pTau217, pTau181, GFAP, NfL) but less on individual rates of change (0.44, 95% CI 0.37--0.50, for pTau217). Assay-specific slope variance was approximately zero, so disagreement was predominantly random. Three-sample single-assay slope reliability was at most 0.40 (0.34--0.46) for pTau217, 0.42 (0.33--0.51) for pTau181, 0.47 (0.37--0.60) for GFAP, 0.52 (0.40--0.64) for NfL, and 0.10 (0.03--0.20) for A{beta}42/40. Two pTau217 measurements had to differ by 65%--131%, depending on the assay, to exceed measurement noise. Detecting 25% slowing of pTau217 change required 924 (598--1,468) to 4,030 (2,091--9,256) participants per arm, or 532 (357--778) to 965 (655--1,431) with averaged measures. In A4/LEARN, single-assay pTau217 reliability was 0.54 (0.46--0.61), and a 7.3- rather than 4.8-year span raised it by 0.10 (0.00-0.22); a fourth sample within it added little. DISCUSSION: With three single-assay samples, much of an individual's measured change is noise. Longer spans, endpoint replication, and assay choice, rather than additional intermediate samples, are needed for reliable serial testing and trials.
Apareció: jueves, 19 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.